The short version
GLP-1 receptor agonists are among the most effective weight loss medications available. They are also associated with a meaningful risk of lean muscle loss if not supported by adequate protein intake and resistance exercise. Research suggests that between 25 and 40 per cent of weight lost on these medications can come from lean mass (which includes muscle) rather than fat. This is a well-documented clinical finding, and addressing it proactively is part of what responsible prescribing looks like. This article explains the mechanism, the evidence, and what good clinical management involves.
Why This Matters Now
GLP-1 receptor agonist prescriptions in Australia increased by more than 500 per cent between 2019 and 2025. As more people access these medications, both through medical clinics and through online prescription services with minimal clinical oversight, the muscle loss question has become one of the most clinically important conversations in weight management.
The concern is not with the medications themselves. Used well and supported appropriately, GLP-1 receptor agonists represent a genuine advance in obesity medicine. The concern is with the gap between what these medications can do and what many patients are being told about how to protect their body composition while using them.
How GLP-1 Medications Affect Body Composition
GLP-1 receptor agonists work primarily by reducing appetite through effects on the hypothalamus and slowing gastric emptying. The result is a significant reduction in caloric intake. Weight loss follows. However, when caloric intake drops substantially, the body does not draw exclusively from fat stores. It draws from whatever fuel is most accessible, and in the absence of adequate protein and stimulating the muscles through resistance exercise, a meaningful proportion of that comes from lean muscle tissue.
This is not a unique feature of GLP-1 medications. It is a feature of significant caloric restriction in general. What distinguishes the GLP-1 context is the magnitude of appetite suppression, which can be considerable, and the speed of weight loss that follows. Faster, more substantial weight loss creates a higher risk of lean mass loss if the clinical management does not actively counteract it.
What The Research Shows
Studies examining body composition changes during GLP-1 treatment have found that lean mass can account for a substantial proportion of total weight lost. Analysis of the STEP 1 trial, one of the major clinical trials for semaglutide in obesity, found that lean body mass loss was a significant component of total weight loss, with some estimates placing the proportion of lean mass loss at 25 to 40 per cent of total weight reduction (Wharton et al., 2021). Similar findings emerged from analysis of tirzepatide trial data in the SURMOUNT-1 study (Look et al., 2025).
These are not fringe findings. They are published in peer-reviewed literature from the largest trials in this space, and they have direct implications for how these medications should be managed clinically.
The body composition consequences of lean mass loss, including reductions in resting metabolic rate, muscle strength, and long-term weight maintenance capacity, are covered in our Why The Scale Number Does Not Tell The Whole Story blog.
Why Muscle Loss Matters
Muscle mass is metabolically active tissue. It is one of the primary determinants of resting energy expenditure, which means that losing lean mass during weight loss reduces the number of calories the body burns at rest. This creates a compounding problem: the weight loss achieved on medication becomes harder to maintain once the medication is stopped or reduced, because the metabolic rate has declined alongside the lean mass.
Muscle loss also affects physical function, strength, and falls risk, particularly in older adults. Research consistently shows that low muscle mass is associated with significantly elevated mortality risk, with premature death risk increased by up to 1.57 times in people with sarcopenia. These are not cosmetic concerns. They are clinical ones.
A systematic review in Nutrition Reviews found that resistance training during energy restriction significantly reduces lean mass loss compared with caloric restriction alone (Cava et al., 2017). The intervention is available, the evidence supports it, and it should be part of the clinical plan from the outset, not an afterthought.
The Two Evidence-Based Strategies
The research on mitigating muscle loss during GLP-1 treatment points consistently toward two interventions.
The first is adequate protein intake. Current evidence supports a target of 1.2 to 1.6 grams of protein per kilogram of body weight per day for people actively losing weight on these medications. This is considerably higher than the standard dietary guidelines for the general population. Meeting this target requires active attention and usually dietitian input, particularly given that GLP-1 medications suppress appetite, which can make it easy to undereat protein without realising it.
The second is progressive resistance exercise. Two or more sessions per week of resistance training, the kind that applies load to muscle groups and progressively increases over time, provides the stimulus that tells the body to preserve lean mass rather than break it down. Aerobic exercise has cardiovascular and metabolic benefits but does relatively little to protect lean mass. Both are valuable. Neither replaces the other.
What Good Clinical Management Looks Like
GLP-1 receptor agonists are prescription medications. Individual suitability requires clinical assessment, and appropriate use requires ongoing monitoring. A clinical environment that prescribes these medications without a baseline assessment of body composition, without dietitian guidance on protein targets, without an exercise plan, and without regular monitoring is not providing complete care.
Regular body composition monitoring, rather than scale weight alone, is the appropriate standard for tracking progress on these medications. The scale can show weight loss while masking a deteriorating lean mass to fat ratio. Body composition assessment, tracking fat mass, lean mass, and visceral fat separately over time, reveals the full clinical picture.
We cover body composition assessment in detail on our Body Composition Scans page. If you are on or considering weight loss medication and have questions about how your body composition is being monitored, that is a question worth raising in your next clinical consultation.
For a broader discussion of what the evidence shows on GLP-1 medications and specific considerations including alcohol, see our Alcohol And GLP-1 Medications blog.
For women with PCOS, GLP-1 receptor agonists carry additional clinical relevance given the central role of insulin resistance in the condition. The emerging evidence on GLP-1 medications and hormonal outcomes is covered in our PCOS And Weight Management master blog.
This article is general information only and not personal medical advice. GLP-1 receptor agonists are prescription-only medications. Suitability for any weight loss medication requires individual clinical assessment with a qualified health professional. Not all treatments are suitable for every person.
Looking Forward
The patients who do best on these medications are those who receive complete clinical support: a prescriber who monitors progress, a dietitian who manages protein and nutrition, and an exercise plan that actively protects lean mass. The medication is one component of a system. When the system is complete, the outcomes are considerably better than when the script is the whole plan.
If you would like to discuss weight management medication in the context of a full clinical assessment, that is what we offer at Alevia. You can also read more about what causes weight gain biologically in our What Causes Weight Gain? article.
Evidence Notes
Wharton, S., et al. (2021). Impact of semaglutide on body composition in adults with overweight or obesity: exploratory analysis of the STEP 1 Study. Obesity, 29(S1). https://pmc.ncbi.nlm.nih.gov/articles/PMC8089287/
Look, M., Dunn, J.P., Kushner, R.F., et al. (2025). Body composition changes during weight reduction with tirzepatide in the SURMOUNT-1 study. Diabetes, Obesity and Metabolism. https://pubmed.ncbi.nlm.nih.gov/39996356/
Cava, E., Yeat, N.C., & Mittendorfer, B. (2017). Preserving healthy muscle during weight loss. Advances in Nutrition, 8(3), 511-519. https://pubmed.ncbi.nlm.nih.gov/20591106/
